Men/women | 3/6 | 19/8 | p<0.05 |
Age in years, mean (SD) | 64.1 (9.5) | 60.8 (10.6) | NS |
CNS involvement | 0 | 8/27 | NS |
Autonomic disturbances* | 2/8 | 8/18 | NS |
Tumour type | | | p<0.05† |
Lung | 0 | 13/27 | |
Lymphoma | 1/9 | 4/27 | |
Breast | 5/9 | 0 | |
Ovarian | 0 | 2/27 | |
Prostate | 0 | 3/27 | |
Others‡ | 3/9 | 5/27 | |
PNS–tumour time interval in months | −8.3 (11.7) | −3.6 (14.0) | NS |
Treatment of the neuropathy* | | | |
Tumour treatment | 8/9 | 17/20 | NS |
Chemotherapy | 4/9 | 11/20 | NS |
Immunosuppressant/immunomodulatory therapy | 6/9 | 11/20 | NS |
Rankin score (median (25% and 75% percentile)) | | | |
At diagnosis | 2 (1.9 and 2.7) | 3 (2.1 and 3.3) | NS |
After one year | 2 (1.5 and 2.5) | 4 (1.5 and 5.0) | p<0.05 |
Course of the neuropathy | | | p<0.05† |
Improved | 2/9 | 2/20 | |
Stable | 7/9 | 6/20 | |
Deteriorated | 0 | 12/20 | |
Type of neuropathy | | | NS† |
Sensorimotor | 7/9 | 16/27 | |
GBS/CIDP | 0 | 4/27 | |
Multiplex | 2/9 | 0 | |
Single system/isolated (motor/sensory/autonomic) | 0 | 7/27 | |